Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters' option to purchase additional shares
MWN-AI** Summary
On March 10, 2026, Medline Inc. (Nasdaq: MDLN) announced the successful closing of a secondary offering involving 86,250,000 shares of its Class A common stock, priced at $41.00 per share. The offering was initiated by selling stockholders associated with notable investment firms, including Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC, and a subsidiary of the Abu Dhabi Investment Authority. This secondary offering was fully subscribed, accounting for a complete exercise of the underwriters' option to purchase an additional 11,250,000 shares.
Importantly, Medline did not partake in the sale of shares, nor did it receive any proceeds from the transaction. Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan acted as global coordinators and joint bookrunning managers for the offering. A comprehensive list of other financial institutions involved includes Barclays, Citigroup, and Deutsche Bank Securities, among others, which functioned in various managerial roles throughout the offering process.
Medline, headquartered in Northfield, Illinois, is recognized as the largest provider of medical-surgical products and supply chain solutions, servicing multiple points of care globally. The company's expansive operations span over 100 countries and employ more than 45,000 individuals, emphasizing its significant role in enhancing healthcare delivery through its diverse product portfolio.
The announcement also featured a note regarding forward-looking statements, cautioning that actual results may deviate due to various risks and uncertainties beyond Medline's control. The investors and stakeholders are encouraged to review the detailed risk factors as disclosed in the company's filings with the SEC. For additional inquiries, Medline has provided contact details for its investor relations and media relations teams.
MWN-AI** Analysis
On March 10, 2026, Medline Inc. successfully closed a secondary offering of 86.25 million shares of its Class A common stock at a price of $41.00 per share, facilitated by key stakeholders and private equity firms, including Blackstone, The Carlyle Group, and Hellman & Friedman. Crucially, Medline did not issue any new shares nor receive any proceeds from this offering, as the shares were sold solely by existing shareholders. This highlights a significant liquidity event for the selling stockholders rather than a capital-raising effort for the company.
Investors should consider several factors following this announcement. Firstly, the involvement of prominent private equity firms indicates a strong vote of confidence in Medline’s business model and future potential. Such backing typically connotes stability and future growth potential, especially in the healthcare supplies sector, which remains robust amid ongoing demands for medical products.
However, a secondary offering can lead to short-term pressure on the stock price due to increased supply. Should the market surmise that this offering signals an overvaluation of Medline’s stock, a temporary decline in share price could result as the market adjusts to the influx of shares.
Furthermore, potential investors should closely examine Medline's operational performance post-offering. Maintaining growth trajectories in revenue and operational efficiency will be key indicators of the company’s resilience. Keeping an eye on analyst reports and quarterly earnings results will provide deeper insights into how the company's fundamentals are evolving.
The market response to this secondary offering will be crucial. A stable share price following the offering may suggest strong institutional support, while volatility could present a buying opportunity for discerning investors. Overall, monitoring Medline's strategic initiatives and market conditions will be essential for making informed investment decisions in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock.
Medline did not sell any shares of Class A common stock in the offering and did not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan acted as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair acted as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler Financial Group, Inc., R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners acted as co-managers for the offering.
The offering of these securities was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar words or phrases that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainty, and changes in circumstances, many of which are beyond our control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor Relations:
Karen King
Global Head Investor Relations
Patrick Flaherty
Director, Investor Relations
(847) 247-7222
IR@medline.com
Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com
Source: Medline Inc.
FAQ**
How might the closing of the secondary offering of 86,250,000 shares by selling stockholders impact Medline Inc. (MDLN) stock performance moving forward?
What are the potential implications for Medline Inc. (MDLN) given that the company did not sell any shares in this offering and received no proceeds?
How do the affiliations of the selling stockholders, including Blackstone Inc. and Carlyle Group, influence the market perception of Medline Inc. (MDLN)?
In light of the recent secondary offering, what strategies does Medline Inc. (MDLN) plan to pursue to ensure sustained growth and resilience in the medical supply chain market?
**MWN-AI FAQ is based on asking OpenAI questions about Medline Inc. (NASDAQ: MDLN).
NASDAQ: MDLN
MDLN Trading
0.39% G/L:
$43.4875 Last:
1,392,985 Volume:
$43.525 Open:
